Skip to main content
. 2022 Nov 2;12:18439. doi: 10.1038/s41598-022-21891-0

Figure 2.

Figure 2

Represented the ratios (a), median fluorescence intensity (b) and adjusted expression (c) of C5AR1, CLEC4A and NLRP3 proteins on CD3+ lymphocytes between non-malignant pulmonary diseases (n = 10) and early-stage NSCLC patients (n = 63). Median fluorescence intensity of CD3+NLRP3+ in early-stage NSCLC patients was 1585 [range 478–5224] which was higher than non-malignant pulmonary diseases, 899 [range 354–1888, p = 0.01]. The limited number of patients with non-malignant pulmonary disease in our study impacted the ability to show if PBMCs protein expression as a biomarker could discriminate between these conditions.